Apellis(US:APLS)2023-07-31 14:32SYFOVRE Safety and Usage - Over 68,000 vials of SYFOVRE have been distributed since launch[6] - There have been seven confirmed reports of retinal vasculitis (RV) in the real world, and one additional reported event is being evaluated[6] - Market research indicates that 13 retina specialists surveyed plan to continue using SYFOVRE as they had been prior to the vasculitis events[9] - Manufacturing processes and drug product quality assessments found no single manufacturing lot implicated, no manufacturing issues impacting product quality, no quality issues, and no contaminants discovered[8] Financial Performance - Apellis' cash of $616 million as of June 30, 2023, combined with expected revenues and Sobi reimbursements, is expected to fund operations into Q1 2025[13] - EMPAVELI U S Net Product Sales were $22.3 million in 2023, compared to $15.7 million in 2022[14] - SYFOVRE U S Net Product Sales reached $67.3 million[14] - Total revenue was $95.0 million, compared to $16.3 million in 2022[14] - Net loss was $(122.0) million, compared to $(156.0) million in 2022[14] Clinical Trial Data - SYFOVRE continues to show increasing effects over time in the GALE long-term extension study[15]